Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Nom du journal : Clin Transl Radiat Oncol
Année : 2023
Volume : 40
Page de départ : 100613
